b'15For a once-daily non-opioid treatmentGo With ANJESOThe first and only once-daily IV analgesic 1,*Up to Demonstrated COX-2Once-dailyHOURS 24 hourssafety and preferential1 pain relief 1,* tolerability1 IV NSAID2,3, IV push*When initiating ANJESO, monitor patient pain response. If patient experiences inadequate analgesia during the 24-hour dosing interval, consider adding a short-acting, non-NSAID,immediate-release analgesic.1The mechanism of action of ANJESO, like other NSAIDs, is not completely understood, but involves inhibition of both COX-1 and COX-2 pathways. COX-2 activity is based onin vitro data, not clinical trial data.1COX-1, cyclooxygenase 1; COX-2, cyclooxygenase 2; IV, intravenous; NSAID, nonsteroidal anti-inflammatory drug.INDICATIONANJESO is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.Limitation of Use: Because of delayed onset of analgesia, ANJESO alone is not recommended for use when rapid onset of analgesia is required.IMPORTANT SAFETY INFORMATIONWARNING: RISK OF SERIOUS CARDIOVASCULAR ANDGASTROINTESTINAL EVENTSCardiovascular Risk Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of seriousTo learn more, please visit cardiovascular thrombotic events, including myocardial infarction and stroke, which can beANJESO.comfatal. This risk may occur early in treatment and may increase with duration of use. ANJESO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients witha prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.Please see brief summary of full Prescribing Information on inside pages and additional Important Safety Information on back cover.20-MCAM-0071_b_Branded_JrnlAd_TheCompendium_DR2.indd 1 5/11/20 2:03 PM'